Navigation Links
BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
Date:8/1/2008

---------

MBP8298 (dirucotide) is a synthetic peptide that consists of 17 amino acids having a sequence identical to that of a portion of human myelin basic protein (MBP). MBP8298 (dirucotide) is being developed for the potential treatment of multiple sclerosis (MS), an autoimmune disease caused by immune attack against normal components of the central nervous system. The sequence of MBP8298 is associated with the autoimmune process in MS patients with certain immune response genes (HLA types DR2 and/or DR4); MS patients having these genes represent 65 to 75 percent of all MS patients.

The apparent mechanism of action of MBP8298 (dirucotide) is the induction or restoration of immunological tolerance with respect to ongoing immune attack as a result of high doses of peptide delivered periodically by the intravenous route. The potential benefit of MBP8298 (dirucotide) for any individual patient is therefore expected to be related to the role this peptide plays in that patient's immune system. The degree of immunomodulation achieved will depend on the relationship among the peptide, HLA molecules and T cells.

The results of phase II and long-term follow-up treatment of MS patients with MBP8298 (dirucotide), published in 2006 in the European Journal of Neurology (EJN), showed that MBP8298 (dirucotide) safely delayed median time to disease progression for five years (versus placebo) in progressive MS patients with HLA types DR2 and/or DR4. Thus, MBP8298 (dirucotide) has the potential to be used as a tailored therapy for patients genetically determined to express the appropriate HLA molecules.

About Multiple Sclerosis

------------------------

Multiple sclerosis (MS) is thought to affect as many as 2.5 million people worldwide, including approximately 75,000 in Canada, 400,000 in the United States and more than 500,000 in Europe. It is a disease that affects more women than men, with onset typically occurring between 20 and 50 year
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/qfxkcq/global_cell ... Cell Therapy Market Outlook 2020 " report to ... tissue and regenerative medicine is expected to have huge ... could help in the growth of deregulated organs. Several ... are unable to form new tissue or sometimes organ ...
(Date:5/20/2015)... Agricultural firm H.J. Baker & Bro., Inc. today ... Since the purchase of Tiger Industries and Tiger-Sunbelt ... H.J. Baker has leveraged the innovation of the Tiger-Sul ... of product offerings and solutions expertise. The deal brought ... of Tiger-Sul, transforming the company into a leading enterprise ...
(Date:5/20/2015)... -- Resolution Bioscience announced today the successful results from their ... blood-based liquid biopsy for an ALK-gene fusion driver mutation ... common form of this cancer. Researchers or clinicians can ... therapies and direct them into clinical trials with a ... the CLIA authority in Washington State ...
(Date:5/20/2015)... May 20, 2015 The Greater ... not-for-profit organization, is pleased to announce they are donating ... Day. These donations represent the effort and commitment of ... the GGI partner sites in 2014. , With ... greater good of clinical trial participation, GGI supports International ...
Breaking Biology Technology:Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3Agricultural Firm H.J. Baker & Bro., Inc., Celebrates 10 Years Since Acquisition Of Tiger-Sul 2Agricultural Firm H.J. Baker & Bro., Inc., Celebrates 10 Years Since Acquisition Of Tiger-Sul 3Resolution Bioscience Receives CLIA Certification for its Diagnostic Laboratory and Launches CLIA-Certified Liquid Biopsy for Lung Cancer 2The Greater Gift Initiative Donates over 10,000 Vaccines in Honor of International Clinical Trials Day 2
... Jan. 2 Bionovo, Inc.,(Nasdaq: BNVI ... that can be used to identify estrogenic drugs ... Cellular Endocrinology, showed,that the new regulatory elements can ... and allow for more,accurate prediction of specific tissue ...
... published today in the New England Journal of Medicine ... store kidneys for transplantation offers significant benefits in kidney ... a traditional "ice box", or cold storage. Unlike ... and vascular performance of the organ in real time, ...
... Therapeutics,(Nasdaq: NKTR ) today announced that ... pulmonary delivery assets, technology, and intellectual,property to Novartis ... completed,on December 31, 2008. , ... certain dry powder and,liquid pulmonary formulation and manufacturing ...
Cached Biology Technology:Bionovo Publishes Discoveries in Predictable Tissue Selectivity for Selective Estrogen Receptor Modulators Platform 2Bionovo Publishes Discoveries in Predictable Tissue Selectivity for Selective Estrogen Receptor Modulators Platform 3Study Shows Machine Perfusion Significantly Improves Transplant Results 2Study Shows Machine Perfusion Significantly Improves Transplant Results 3Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million 2
(Date:5/20/2015)... , May 20, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/h8t4x6/5year ) has announced the addition ... the Global Iris Recognition Market"  report ... , ,This research service analyses trends ... the government and commercial sectors, globally. ...
(Date:5/18/2015)... , May 18, 2015 Fingerprint ... sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if ... June until and including Q3 2015 and the sensors will ... . Communicated order values for 2015 hereby amount to 740 ... Q1 2015 of 140 MSEK and a number of smaller ...
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, ... the start of a new Phase III double blind, ... its novel formulation, CM-AT, on all children ages 3-8 ... its FDA Phase III double blinded clinical trial for ... low levels of the digestive enzyme chymotrypsin. This new ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... unseen details of an anthrax bacteriophage a virus that ... it infects its host, and providing an initial blueprint for ... for the detection and destruction of anthrax and other potential ... spore-binding phage 8a (or SBP8a, for short), is too ...
... University of Gothenburg,s Sahlgrenska Academy have discovered a brand new ... around the world, three of them in the Gothenburg area, ... Sweden was out kayaking when he went down with acute ... to hospital where it was found that he was also ...
... dental X-rays to predict who is at risk of fractures, ... reported in the journal Nature Reviews Endocrinology . ... Sahlgrenska Academy and Region Vstra Gtaland demonstrated that a sparse ... is linked to a greater chance of having previously had ...
Cached Biology News:Researchers reveal SBP8a configurations 2Researchers reveal SBP8a configurations 3New tick-borne disease discovered in Gothenburg 2Dental X-rays can predict fractures 2
... 60kDa (A) and 36kDa (C) subunits ... 7.5, 500mM NaCl, 60mM 2-mercaptoethanol, 1mM ... DTT, and 0.1mg/ml serum albumin Properites: ... proteins. Purification: DEAE chromatography, aminohexyl-agarose and ...
... preparative LC/MS, using mass numbers as a ... ideal for performing investigation and research of ... both analytical and preparative operation. Switching between ... the software. This support provides a quick ...
... Tracker Intracellular Localization Kit provides a straight ... siRNA, of your design, in an efficient ... experiments. Subcellular localization and functional inhibition of ... introduction of the labeled siRNA into mammalian ...
... The Label IT siRNA Tracker Intracellular ... provides a straight forward approach to ... your design, in an efficient yet ... experiments. Subcellular localization and functional inhibition ...
Biology Products: